opioid epidemic in the United States

opioid epidemic in the United States
Name	Opioid epidemic in the United States
Date	1990s–present
Place	United States
Deaths	500,000+ (est.)
Causes	Prescription opioid misuse, heroin, synthetic opioids

opioid epidemic in the United States The opioid epidemic in the United States is a prolonged public health crisis marked by rising rates of opioid prescribing, opioid use disorder, overdose deaths, and social consequences. Major stakeholders include federal agencies, state governments, healthcare systems, pharmaceutical companies, advocacy groups, and affected communities across urban and rural settings. Responses have involved legislation, litigation, clinical guideline changes, and public health interventions.

Background and history

The crisis traces roots to shifts in pain management and pharmaceutical promotion during the 1990s involving Food and Drug Administration, Purdue Pharma, University of Virginia Health System, Veterans Health Administration, and medical societies such as the American Medical Association and American Pain Society. Early phases included increased prescribing of drugs like OxyContin and Vicodin after influential publications and guideline endorsements from institutions like Institute of Medicine and Joint Commission on Accreditation of Healthcare Organizations. A transition occurred in the 2000s toward nonmedical use and diversion noted by surveillance from the Centers for Disease Control and Prevention and National Institute on Drug Abuse. Subsequent waves featured rising heroin use linked to suppliers in regions such as Mexican drug cartels and later proliferation of synthetic opioids like fentanyl traced to sources connected with China and transnational distribution networks discussed in reports by the Drug Enforcement Administration and United Nations Office on Drugs and Crime.

Scope and epidemiology

Epidemiological data compiled by the Centers for Disease Control and Prevention, National Center for Health Statistics, Substance Abuse and Mental Health Services Administration, and National Vital Statistics System document sharp increases in overdose mortality and morbidity. Demographic analyses reference impacted populations in states like Ohio, West Virginia, Kentucky, Pennsylvania, and Massachusetts as well as cities including Baltimore, Philadelphia, Detroit, and New York City. International comparisons consider trends in Canada, United Kingdom, Australia, and regions monitored by the World Health Organization. Research from institutions such as Johns Hopkins University, Columbia University, Harvard Medical School, Yale School of Medicine, and University of California, San Francisco has quantified burden using measures developed by the Global Burden of Disease Study and reported in journals like The New England Journal of Medicine, The Lancet, and JAMA.

Causes and contributing factors

Multiple drivers include aggressive marketing by firms such as Purdue Pharma, prescribing practices influenced by academic centers and specialty societies including American Academy of Pain Medicine and American Society of Anesthesiologists, and policy shifts at institutions like the Department of Veterans Affairs and Medicare. Socioeconomic factors tied to regions affected by industrial decline reference research from Brookings Institution, The Urban Institute, and Pew Charitable Trusts. Supply-side dynamics involve criminal enterprises like Mexican cartels and trafficking routes analyzed by the Drug Enforcement Administration and Customs and Border Protection, while pharmaceutical manufacturing and export relationships implicate entities in China and multinational corporations such as Johnson & Johnson. Public health surveillance, clinical decision-making, and reimbursement systems from programs like Medicaid and Medicare Part D shaped access to opioids and alternatives, with policy reviews by the Office of National Drug Control Policy and legal scrutiny from the Department of Justice.

Public health and policy responses

Federal and state responses include guidelines from the Centers for Disease Control and Prevention and legislative actions like the Comprehensive Addiction and Recovery Act and the 21st Century Cures Act. Litigation against manufacturers led to settlements involving Purdue Pharma, distributor entities such as McKesson Corporation, Cardinal Health, and AmerisourceBergen, and retailers including Walmart and Walgreens. Public health programs have mobilized city and state health departments (e.g., New York City Department of Health and Mental Hygiene, Ohio Department of Health) and federal agencies including Substance Abuse and Mental Health Services Administration, Department of Health and Human Services, and Centers for Medicare & Medicaid Services. Advocacy organizations like Shatterproof, Partnership to End Addiction, Harm Reduction Coalition, and families represented by groups such as National Families in Action shaped policy debates, while major philanthropic actors including the Bill & Melinda Gates Foundation and the Robert Wood Johnson Foundation funded research and interventions.

Treatment, prevention, and harm reduction

Clinical treatments include medications for opioid use disorder such as methadone, buprenorphine, and naltrexone provided through programs certified by the Substance Abuse and Mental Health Services Administration and clinics licensed under state laws modeled on programs like those in Vermont and Massachusetts. Harm reduction strategies championed by organizations like the Harm Reduction Coalition and implemented in jurisdictions including San Francisco, Seattle, and Philadelphia feature naloxone distribution, syringe services programs, and pilot supervised consumption sites informed by evidence from Portugal and Canadian provinces like British Columbia. Prevention efforts leverage school-based curricula developed with agencies such as Centers for Disease Control and Prevention and community initiatives supported by Robertson County Health Department-style local health agencies and nonprofits. Research trials at centers including National Institutes of Health and universities such as Duke University and University of Pennsylvania evaluate new pharmacotherapies, behavioral interventions, and integrated care models.

Legal and criminal justice aspects

Criminal justice responses involve law enforcement agencies like the Drug Enforcement Administration and state police, prosecutorial actions by United States Department of Justice and local district attorneys, and court systems including federal courts in districts such as the Southern District of New York. Policy shifts toward diversion and treatment cite programs like drug courts in Miami-Dade County and reforms enacted in states such as Oregon and California. Major litigation produced settlements and bankruptcy proceedings involving Purdue Pharma and resulted in oversight by trustees and judges in United States Bankruptcy Court for the Southern District of New York. Civil suits led by coalitions of state attorneys general from offices in Ohio Attorney General and New York State Attorney General secured funds for abatement and remediation managed via settlement agreements with entities including McKesson Corporation and AmerisourceBergen. International law enforcement cooperation has included agencies such as INTERPOL and bilateral initiatives between the United States and Mexico.

Category:Opioid crisis